摘要
为评价六君子汤联合西医疗法治疗慢性阻塞性肺疾病(COPD)稳定期有效性和安全性。该研究系统检索三大英文数据库和四大中文数据库,检索时间均从建库至2020年4月1日,根据预先确定的纳排标准筛选相关的随机对照试验(RCT),并提取资料。采用"Cochrane偏倚风险评估工具"对所纳入研究进行方法学质量评价。应用RevMan 5.3软件进行数据分析。结果共检索出401篇文献,最终纳入17个RCTs,总样本量1 447例,纳入研究总体质量不高。Meta分析结果显示,在降低中医症状积分方面,六君子汤联合西医常规治疗或沙美特罗替卡松粉吸入剂优于单独使用西医常规治疗或沙美特罗替卡松粉吸入剂;在降低改良版英国医学研究委员会呼吸问卷(mMRC)分级方面,六君子汤联合沙美特罗替卡松粉吸入剂优于单独使用沙美特罗替卡松粉吸入剂;在降低慢性阻塞性肺疾病患者自我评估测试问卷(CAT)评分方面,六君子汤联合西医常规治疗优于单独使用西医常规治疗;在延缓第1秒用力呼气容积(FEV1)或其占预计值%下降方面,六君子汤联合西医常规治疗或沙美特罗替卡松粉吸入剂优于单独使用西医常规治疗或沙美特罗替卡松粉吸入剂;在延缓FEV1与用力肺活量之比(FEV1/FVC)下降方面,六君子汤联合西医常规治疗优于单独使用西医常规治疗,而六君子汤联合沙美特罗替卡松粉吸入剂与单独使用沙美特罗替卡松粉吸入剂无统计学差异;在降低急性加重率方面,六君子汤联合沙美特罗替卡松粉吸入剂与单独使用沙美特罗替卡松粉吸入剂无统计学差异。其他结局指标或者六君子汤联合其他西医疗法,由于仅纳入1项研究,无法进行Meta分析,而无法得出结论。由于部分研究未提及不良反应,故不能对六君子汤联合西医疗法的安全性作出肯定性评价。受纳入文献质量、数量的限制,六君子汤联合西医疗法治疗COPD稳定期的�
To systematically review the efficacy and safety of Liujunzi Decoction combined with Western medicine in the treatment of stable chronic obstructive pulmonary disease(COPD). Three English databases and four Chinese databases were systematically searched from the database establishment to April 1, 2020. We screened randomized controlled trial(RCT) according to the pre-determined inclusion and exclusion criteria, then extracted data. Methodological quality of included studies was assessed with Cochrane bias risk evaluation tool. Data were analyzed by using RevMan 5.3. A total of 401 articles were retrieved and finally 17 RCTs were included in this study, involving 1 447 patients, and the overall quality of the included studies was not high. Meta-analysis showed that, in reducing traditional Chinese medicine symptom score, Liujunzi Decoction combined with conventional Western medicine or Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was superior to conventional Western medicine or Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation alone. In reducing the grade of modified medical research council(mMRC), Liujunzi Decoction combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was superior to Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation alone. In reducing COPD assessment test(CAT) score, Liujunzi Decoction combined with conventional Western medicine was superior to conventional Western medicine alone. In delaying the decline of forced expiratory volume in one second(FEV1) or % in the expected value, Liujunzi Decoction combined with conventional Western medicine or Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was superior to conventional Western medicine or Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation alone. In delaying the decline of ratio of FEV1 to forced vital capacity(FEV1/FVC), Liujunzi Decoction combined with conventional Western medicine was superior to conventional
作者
范艺龄
苗青
廖星
樊长征
樊茂蓉
曹庆
王宁
马秋晓
郝娅妮
FAN Yi-ling;MIAO Qing;LIAO Xing;FAN Chang-zheng;FAN Mao-rong;CAO Qing;WANG Ning;MA Qiu-xiao;HAO Ya-ni(Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Center for Evidence-based,Chinese Medicine,Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Beijing University of Chinese Medicine,Beijing 100029,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2020年第22期5331-5343,共13页
China Journal of Chinese Materia Medica
基金
中国中医科学院“十三五”重点领域研究重点项目(Z0545)
中国宋庆龄基金会慢阻肺临床研究专项(2018MZFZY-010)。
